Background New drug treatments, clinical trials, and standards of quality for assessment of
evidence justify an update of evidence-based recommendations for the pharmacological …

Background The available drugs to treat neuropathic pain have incomplete efficacy and
dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and …

Neuropathic pain, caused by various central and peripheral nerve disorders, is especially
problematic because of its severity, chronicity and resistance to simple analgesics. The …

BACKGROUND: Neuropathic pain (NeP), redefined as pain caused by a lesion or a disease
of the somatosensory system, is a disabling condition that affects approximately two million …

Background Drugs for neuropathic pain have incomplete efficacy and dose-limiting side-effects
when given as monotherapy. We assessed the efficacy and tolerability of combined …

Neuropathic pain is caused by disease or injury of the nervous system and includes various
chronic conditions that, together, affect up to 8% of the population. A substantial body of …

The term “nociplastic pain” was introduced by the International Association for the Study of
Pain (IASP) in 2017 as a third mechanistic pain descriptor in addition to nociceptive and …

Background Pharmacotherapy remains an important modality for the treatment of neuropathic
pain. However, as monotherapy current drugs are associated with limited efficacy and …

Background Chronic pain can often occur after surgery, substantially impairing patients’
health and quality of life. It is caused by complex mechanisms that are not yet well understood. …

There has been an increase in the number of chronic pain clinical trials in which the treatments
being evaluated did not differ significantly from placebo in the primary efficacy analyses …